Authors
Latest:
Dr Vaz Batista on Treating Patients With HER2+ Breast Cancer and Leptomeningeal CarcinomatosisMarta Vaz Batista, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis, as evaluated in cohort 5 of the phase 2 DEBBRAH study.
Latest:
Camidge and Arslan Calculate the “Impact Factor” of a Career in MedicineDrs Camidge and Arslan discuss Dr Arslan’s experience providing emergency medical care and the curiosity that led him to pursue a career in industry.
Latest:
Frontline Therapeutic Planning for Metastatic Renal Cell CarcinomaIn this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.
Latest:
Dr. Park on the Role of Cemiplimab in Advanced Basal Cell CarcinomaSoo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.
Latest:
Dr. Giaconne on the Lack of Funding for Rare Cancers ResearchGiuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.
Latest:
Dr Olazagasti on Disparities in Lung Cancer Screening Rates for Hispanic Head and Neck Cancer SurvivorsCoral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr Gershon on Deep Responses With Mirdametinib in NF1-PNTimothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.
Latest:
Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in CancerRanjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.
Latest:
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment LandscapeClosing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Latest:
Dr. Ross on the Role of the Microbiome in CRCHoward M. Ross, MD, discusses the role of the microbiome colorectal cancer.
Latest:
In the Trenches With the FellowsMili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.
Latest:
SCLC: Future Therapies and Advice to Community OncologistsDrs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.
Latest:
Novel Treatment Combinations in Chronic Lymphocytic LeukemiaDr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.
Latest:
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric CancerRutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Latest:
Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSLTracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.
Latest:
Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic LeukemiaKey opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.
Latest:
Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment JourneyAmado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.
Latest:
Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer LandscapeA panel of experts offer future perspectives in HR+ breast cancer.
Latest:
Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced MelanomaIsabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.
Latest:
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer CareShridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Latest:
Examining the Promise of Multicancer Early Detection Tests: Looking to the FutureIn this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.
Latest:
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MDIn this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.
Latest:
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell MalignanciesPatients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Latest:
Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With CancerNatasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.
Latest:
Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI CancersMarios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.
Latest:
Best Practices in Managing Patients on CapivasertibPanelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.
Latest:
Dr Diaz on the Evolution of Precision Medicine in Cervical CancerJohn Paul Diaz, MD, discusses the evolving use of precision medicine approaches in cervical cancer management.
Latest:
Dr. Munver on the Approval of Mitomycin Gel in Urothelial CancerRavi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.
Latest:
The Future of Lower-Risk MDS: Closing Thoughts and Unmet NeedsPanelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.
